This webinar explores the importance of mental health in pulmonary hypertension management, featuring experts who will discuss the role of mental health professionals, coping strategies, and ways to improve the overall well-being of PH patients.
Webinar: Mental health in pulmonary arterial hypertension Read Post »
New research published in The Lancet on September 19, 2024, suggests that the seratonin pathway might not be a suitable option for pulmonary arterial hypertension therapy. The role of serotonin in pulmonary arterial hypertension has been extensively studied in recent decades, with preclinical data indicating involvement in disease pathogenesis; however, clinical studies up to now
The role of serotonin in pulmonary arterial hypertension has been extensively studied in recent decades, with preclinical data indicating involvement in disease pathogenesis; however, clinical studies have yielded mixed results. New research published in The Lancet suggests that the seratonin pathway might not be a suitable option for pulmonary arterial hypertension therapy. ELEVATE-2 was a
In pulmonary arterial hypertension lung samples researchers have observed elevated asporin levels and found a link between these levels and lower disease severity. Higher levels of asporin appeared to counteract the pathological remodeling of the pulmonary vasculature that characterizes pulmonary arterial hypertension. Jason Hong, MD, PhD, assistant clinical professor at David Geffen School of Medicine
MK-5475 is an experimental soluble guanylate cyclase stimulator which is administered via dry powder inhalation and is designed to potentially mitigate the side effects associated with systemic vasodilation. The results of the INSIGNIA-PAH study published in the Respiratory Journal suggest that MK-5475 reduced pulmonary vascular resistance (PVR) and was well tolerated in patients with pulmonary
CS1 is a HDAC, Histone Deacetylase inhibitor, that works through epigenetic modulation and is being developed by Cereno Scientific as a disease modifying treatment for pulmonary arterial hypertension. CS1 targets the root cause of the disease, aiming to reverse the pathological vascular remodeling of the small lung arteries. The Phase IIa trial evaluated the safety,
Article exploring the serotonin pathway in pulmonary arterial hypertension care published in The Lancet Respiratory Medicine on September 19, 2024, titled “Serotonin pathway blockade in pulmonary arterial hypertension”. The author is Marcin Kurzyna, MD, PhD, FESC Citation Serotonin pathway blockade in pulmonary arterial hypertension, Kurzyna, Marcin, The Lancet Respiratory Medicine, Volume 0, Issue 0, DOI: 10.1016/S2213-2600(24)00291-1
The webinar was hosted by the Alliance for Pulmonary Hypertension on Tuesday, September 17, 2024.
Navigating clinical trials in pulmonary hypertension webinar Read Post »
Abstract “Despite the innovations introduced in the 2022 European Society of Cardiology/European Respiratory Society Guidelines on Pulmonary Hypertension, risk discrimination and management of pulmonary arterial hypertension patients at intermediate risk still represents a grey zone. Additionally, clinical evidence derived from currently available studies is limited. This expert panel survey intends to aid physicians in choosing
The European Society of Cardiology’s Congress is the foremost gathering in the field of cardiology worldwide. This year’s edition took place in London from 30.8-1.9, 2024, and counted 31,700 participants from 162 countries, including 5,400 faculty and presenters, representatives of the National Cardiac Societies and industry partners. Pisana Ferrari, the Alliance for Pulmonary Hypertension’s Secretary
Over the past decade, significant strides have been made in diagnosing and treating pulmonary hypertension, driven by updated criteria and new medications. However, timely diagnosis remains a major challenge, with many patients facing long delays, often waiting years and consulting multiple doctors before receiving an accurate diagnosis. Journalist and healthcare writer Jared Kaltwasser has recently
An article titled “Empowering patient research” which was recently published on the Aeon Psyche newsletter on August 5, 2024, discusses the challenges faced by patients with chronic illnesses and disabilities in the healthcare system, particularly in research and academia. The article advocates for the inclusion of patients as active participants in medical research, arguing that
The findings of study which aimed to evaluate the potential for using resistin as a genetic and biological marker for disease severity and survival in pulmonary arterial hypertension were published on June 6, 2024 in “Pulmonary Research”. Resistin is an adipose-derived hormone (similar to a cytokine). The researchers collected biospecimens, clinical, and genetic data for 1.121 adults
Oral treprostinil is a prostacyclin analogue approved to treat pulmonary arterial hypertension (PAH). A study analysing the practical management of oral treprostinil in patients with pulmonary arterial hypertension has been published on “Respiratory Medicine” Volume 231, 107734, September 2024. The article is based on results of the ADAPT and EXPEDITE trials and expert consensus. The
Aerovate Therapeutics has announced that its pulmonary arterial hypertension (PAH) candidate AV-101 failed to meet its primary endpoint in the Phase IIb portion of the IMPAHCT trial. The Phase IIb portion of the IMPAHCT trial aimed to assess three different doses of AV-101, a novel dry powder inhaled formulation of imatinib. The primary endpoint tested
Colleen Brunetti, Past Chair of the Board of the Pulmonary Hypertension Association, speaks about her experience with the condition and taking part in clinical trials in this video, published on the European Lung Foundation YouTube channel. Read more about Colleen and her book “Defining the new normal: A guide to becoming more than your diagnosis”
The U.S. Food and Drug Administration (FDA) has issued a draft guidance titled “Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies.” This guidance is aimed at assisting medical product sponsors in submitting “Diversity Action Plans” for certain clinical studies. These plans are designed to enhance the enrollment of historically
The Multicomponent Improvement” (MCI) endpoint is a composite endpoint measuring improvement in 6-minute walk distance, reduction or maintenance of low N-terminal pro-BNP levels, and improvement or maintenance of WHO functional class I or II. The American Journal of Respiratory and Critical Care Medicine has published the abstract of a session at the American Thoracic Society
The Pulmonary Hypertension Association (PHA) is holding a webinar of “Fundamentals of Genetic Testing“ on Tuesday, June 11, at 2 p.m. EDT/ 6 p.m. UTC in collaboration with TBX4Life and Fundación Contra la Hipertensión Pulmonar Featured topics include The webinar will be available in English and Spanish. Speakers Harm Jan Bogaard, MD, PhDProfessor of Experimental Pulmonary MedicinePulmonologist, Department
Gossamer Bio and Chiesi Group have announced a a global collaboration agreement to develop seralutinib, an inhaled investigational drug for the treatment of pulmonary arterial hypertension. Seralutinib is currently being investigated in the ongoing global Phase 3 trial, PROSERA, for pulmonary arterial hypertension. This collaboration further enhances the resources and expertise devoted to seralutinib and
